Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study.

Author: AustadJ, BachmannI, BanerjeeR, EidsmoL, FasthA E R, FruehJ, IversenL, OliverJ, OsmancevicA, SkovL, StahleM, TalmeT, de RieM, van de KerkhofP

Paper Details 
Original Abstract of the Article :
To date, biological treatments have been assessed in subjects with a long-term history of psoriasis and previous failures to systemic and topical therapies. In rheumatoid arthritis and other immune-mediated inflammatory diseases, early intensive systemic treatment prolongs treatment-free remission. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/jdv.14979

データ提供:米国国立医学図書館(NLM)

Secukinumab for New-onset Psoriasis: Early Intervention for a More Sustainable Oasis?

Psoriasis, a chronic inflammatory skin condition, can have a significant impact on quality of life. Current treatments often focus on managing existing symptoms, but what if we could intervene earlier and potentially alter the course of the disease? This study explores the potential of early intervention with secukinumab, a biological therapy, in patients with new-onset psoriasis, seeking to understand if early treatment can lead to disease modification and a more sustainable oasis of clear skin. The research aims to provide a better understanding of how early treatment can impact the long-term management of psoriasis.

Exploring a new oasis: Early intervention for psoriasis

This study, called STEPIn, is a randomized, multicenter trial investigating early intervention with secukinumab versus narrow-band ultraviolet B (nb-UVB) phototherapy in patients with new-onset psoriasis. The researchers are exploring whether early intervention with secukinumab can lead to prolonged treatment-free remission, similar to what has been observed in other immune-mediated inflammatory diseases. The findings of this study could revolutionize the way we treat psoriasis, potentially offering a more sustainable path towards clear skin.

Early intervention: A potential key to unlocking a more sustainable oasis

This study sheds light on the potential benefits of early intervention in psoriasis. If successful, it could provide a more sustainable solution for patients, potentially reducing the need for long-term treatment and offering a more stable oasis of clear skin. It's important to note that this study is still ongoing, and more research is needed to understand the full impact of early intervention.

Dr. Camel's Conclusion

The desert of psoriasis can be a challenging landscape to navigate. This study, like a wise camel caravan leader, seeks to find a more sustainable oasis for those with psoriasis. By exploring the potential of early intervention, the researchers are hoping to create a more stable and enduring path towards clear skin.

Date :
  1. Date Completed 2019-02-14
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29633373

DOI: Digital Object Identifier

10.1111/jdv.14979

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.